Tempus AI (TEM) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for May 20, 2025, to be held virtually, with voting available online, by phone, or by mail.
Three key proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as auditor, and approval of reincorporation from Delaware to Nevada.
Only holders of Class A or Class B common stock as of March 25, 2025, are eligible to vote, with Class B shares carrying 30 votes per share.
Voting matters and shareholder proposals
Proposal 1: Elect nine directors to serve until the next annual meeting.
Proposal 2: Ratify PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2025.
Proposal 3: Approve reincorporation from Delaware to Nevada by conversion, with no change to business operations or management.
Shareholders may submit proposals for the 2026 annual meeting between January 20 and February 19, 2026.
Board of directors and corporate governance
Board consists of nine members with diverse backgrounds in technology, healthcare, and investment.
Majority of directors are independent per Nasdaq standards; committees include Audit, Compensation, Nominating and Corporate Governance, and Executive.
Board leadership structure allows CEO to serve as Chair; board actively oversees risk, strategy, and ESG initiatives.
Board and committee meetings had strong attendance in 2024.
Latest events from Tempus AI
- AI-driven insights from proprietary clinical and molecular data are reshaping precision medicine.TEM
Morgan Stanley Technology, Media & Telecom Conference 20263 Mar 2026 - Q4 and 2025 revenue rose 83% year-over-year, with strong Diagnostics and Data growth.TEM
Q4 202524 Feb 2026 - Q2 revenue up 25% to $166M, net loss $552M on IPO costs, cash at $479.7M.TEM
Q2 20242 Feb 2026 - Q3 revenue up 33% YoY; Ambry Genetics acquisition expands growth and capabilities.TEM
Q3 202416 Jan 2026 - AI-powered diagnostics and data platform drives 25% projected revenue growth for 2026.TEM
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Q4 revenue up 35.8%, 2025 guidance raised, and Ambry Genetics acquisition completed.TEM
Q4 20247 Jan 2026 - AI-powered diagnostics and data licensing drive growth, with applications set to lead future revenue.TEM
Morgan Stanley Technology, Media & Telecom Conference7 Jan 2026 - Sustained profitability, data-driven growth, and new product launches set the stage for long-term expansion.TEM
Piper Sandler 37th Annual Healthcare Conference3 Dec 2025 - Key votes include director election, auditor ratification, and Nevada reincorporation approval.TEM
Proxy Filing2 Dec 2025